Prognostic and predictive factors in high-grade gliomas. Experience at our institution

被引:0
作者
Alonso, Diana [1 ]
Matallanas, Manuel [1 ]
Riveros-Perez, Alba [2 ]
Perez-Payo, Maripaz [1 ]
Blanco, Sonia [1 ]
机构
[1] HUCA, Serv Oncol Radioterap, Oviedo, Spain
[2] Hosp Univ Doctor Negrin, Serv Oncol Radioterap, Las Palmas Gran Canaria, Las Palmas, Spain
来源
NEUROCIRUGIA | 2017年 / 28卷 / 06期
关键词
Glioma; Glioblastoma; Astrocytoma; GLIOBLASTOMA; MGMT; CLASSIFICATION; TEMOZOLOMIDE; METHYLATION; TUMORS;
D O I
10.1016/j.neucie.2017.07.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objectiue: To describe and analyse predictive and prognostic factors of overall survival (OS) in high-grade gliomas at our institution. Material and method: All patients diagnosed with grade in (GIII) or grade iv (GIV) gliomas (excluding oligodendrogliomas, oligoastrocytomas or infratentorial gliomas) were prospectively included from November 2010 to August 2014. All were treated with surgery followed by adjuvant radiochemotherapy. The Kaplan-Meier method was used for the statistical analysis, considering a P value <.05 to be significant. Results: 89 patients were studied (18 GIII and 71 GIV). The average age was 60 years and 55% were men. The mean Karnofsky score was 80%. The most common location was the frontal lobe (38%). A total of 65% were partial resections. Complete chemotherapy was administered to 74% and complete RT to 83% of patients. Mean OS was 26.8 8.3 months for GIII and 12.5 1 month for GIV. 72 had died by the end of this study. A total of 40% of patients had MGMT methylation, 7% IDH1 mutation and 47% EGFR amplification. Statistically significant variables for OS were: GIII (P=.020), age <70 years (P=.040), <65 years (P=.013) and <60 years (P=.003), Kamofsky >70% (P=.029), complete radiotherapy (P=.000), complete resection (P=.001), MGMT methylation (P=.042), IDH1 mutation (P=.007) and EGFR non-amplification (P=.034). Additionally, GIII and GN subgroups were independently analysed. In GIII, the only significant biomarker for OS was IDH1 mutation, while in GN, MGMT methylation (P=.023) was significant. Age >70 years old was a significant factor in the GIII-subgroup (P=.040) but not for GIV (P=.166). Conclusions: Data are in line with previous studies, with the exception of age, which does not appear to be significant in GIV. 2017 Sociedad Espanola de Neurocirugia. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 50 条
  • [21] Factors Involved in Preoperative Edema in High- Grade Gliomas
    Saito, Takashi
    Mizumoto, Masashi
    Liang, Hsiang-Kuang
    Nakai, Kei
    Sumiya, Taisuke
    Iizumi, Takashi
    Kohzuki, Hidehiro
    Numajiri, Haruko
    Makishima, Hirokazu
    Tsurubuchi, Takao
    Matsuda, Masahide
    Ishikawa, Eiichi
    Sakurai, Hideyuki
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (11)
  • [22] Pediatric high-grade gliomas
    Kramm, C.
    Rausche, U.
    Butenhoff, S.
    Kuehnoel, C.
    Kunze, C.
    Kortmann, R.
    Wolff, J.
    van Gool, S.
    [J]. MONATSSCHRIFT KINDERHEILKUNDE, 2008, 156 (12) : 1201 - 1207
  • [23] High-Grade Gliomas in Children
    Cage, Tene A.
    Mueller, Sabine
    Haas-Kogan, Daphne
    Gupta, Nalin
    [J]. NEUROSURGERY CLINICS OF NORTH AMERICA, 2012, 23 (03) : 515 - +
  • [24] The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas
    Juratli, T. A.
    Kirsch, M.
    Geiger, K.
    Klink, B.
    Leipnitz, E.
    Pinzer, T.
    Soucek, S.
    Schrok, E.
    Schackert, G.
    Krex, D.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2012, 110 (03) : 325 - 333
  • [25] Ultra-hyper-fractionated radiotherapy for high-grade gliomas
    Frosina, Guido
    Fontana, Vincenzo
    Verzola, Daniela
    Rosa, Alessandra
    Gaggero, Gabriele
    Garibotto, Giacomo
    Vagge, Stefano
    Pigozzi, Simona
    Daga, Antonio
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2021, 99 (12) : 3182 - 3203
  • [26] Identification of P4HA1 as a prognostic biomarker for high-grade gliomas
    Hu, Wan-ming
    Zhang, Ji
    Sun, Shu-xin
    Xi, Shao-yan
    Chen, Zhi-jie
    Jiang, Xiao-bing
    Lin, Fu-hua
    Chen, Zheng-he
    Chen, Yin-sheng
    Wang, Jian
    Yang, Qun-ying
    Guo, Cheng-cheng
    Mou, Yong-gao
    Chen, Zhong-ping
    Zeng, Jing
    Sai, Ke
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2017, 213 (11) : 1365 - 1369
  • [27] Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study
    Fat, Mary Jane Lim
    Maurice, Catherine
    Maganti, Manjula
    Mason, Warren P.
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2018, 45 (01) : 56 - 61
  • [28] Bevacizumab in the treatment of high-grade gliomas: an overview
    Kunnakkat, Saroj
    Narayana, Ashwatha
    [J]. ANGIOGENESIS, 2011, 14 (04) : 423 - 430
  • [29] Stereotactic radiosurgery for recurrent high-grade gliomas
    Kite, Trent
    Yadlapalli, Vineetha
    Herbst, John
    Karlovits, Stephen
    Wegner, Rodney E.
    Shepard, Matthew J.
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2025, 135
  • [30] Positron emission tomography of high-grade gliomas
    Guido Frosina
    [J]. Journal of Neuro-Oncology, 2016, 127 : 415 - 425